SBIR/STTR Research Award
EVALUATING HBVZ10-BASED THERAPIED FOR CCCDNA CLEARANCE: VIROLOGICAL FOUNDATION AND SYNERGISTIC COMBINATIONS
Award amount
$606,178Program and phase
SBIR · Phase IAward year
2025Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HBVtech
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- WEXNYHY4EZB5
- Solicitation number
- PHS 2025-1
- Topic code
- 137
Research abstract
Evaluating HBVZ10-Based Therapies for cccDNA Clearance: Virological Foundation and Synergistic Combinations
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A New HBV Drug For Establishing Durable Antiviral Efficacy of HBV Treatment
- SBIR NIAID TOPIC 084: ""ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION""
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- B-SMART - BROADLY NEUTRALIZING ANTIBODIES FOR SARNA MEDIATED ANTIVIRAL RESPONSE THERAPY
- THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS
Research funding history
3 SBIR/STTR records share this UEI (2020–2025). Reported award amounts total $1,206,046. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services